Castle Biosciences (CSTL)
NASDAQ:CSTL
Want to see CSTL full AI Analyst Report?
Earnings Data
Report Date
Aug 10, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.4Last Year’s EPS
0.15Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated strong commercial momentum across core products—notably DecisionDx‑Melanoma and TissueCypher—with significant year‑over‑year test volume growth (36% core volumes; 58% TissueCypher) and an uplifted full‑year revenue guide. Profitability metrics improved versus prior year (narrower net loss, improved adjusted EBITDA) and the balance sheet remains solid with ~$261.7M in cash and marketable securities. Key negatives are an adjusted gross margin decline versus the prior comparable period, continued negative adjusted EBITDA (albeit improved), operating cash use in Q1, ongoing reimbursement and timing uncertainty for DecisionDx‑SCC and for broad commercialization of Advanced ADTx, and higher operating costs tied to growth and capacity investments. On balance, the positive commercial traction, raised guidance, improving profitability trends, and healthy liquidity outweigh the remaining execution and reimbursement risks.Company Guidance
Strong Q1 Revenue and Raised Full-Year Guidance
Revenue of $83.7 million in Q1 2026. Company raised 2026 revenue guidance to $345 million–$355 million (from $340 million–$350 million), representing high‑teens to low‑20s growth in 2026 over 2025 on an excl. DecisionDx‑SCC and ID Genetics basis.
Robust Core Test Volume Growth
Core test report volumes grew 36% year‑over‑year in Q1 2026. Excluding DecisionDx‑SCC and ID Genetics revenue, Company-reported revenue growth for 2026 is approximately 42% vs 2025.
DecisionDx‑Melanoma Momentum
Delivered 10,021 DecisionDx‑Melanoma test reports in Q1 (16% YoY growth). March 2026 was an all‑time record month. Company expects mid‑ to high‑single digit volume growth for full‑year 2026 and is progressing an FDA submission in 2026 (following prior Breakthrough designation).
TissueCypher Rapid Expansion
TissueCypher test reports rose to 11,745 in Q1 2026 from 7,432 in Q1 2025, a 58% YoY increase. March (and April commentary) were record months. Company expects to add a similar number of tests in 2026 as in 2025, implying ~50% YoY growth for the full year.
Early Traction for Advanced ADTx
Advanced ADTx (limited launch) received ~650 orders in Q1 2026. Prospective multicenter validation published in the Journal of the American Academy of Dermatology shows the test stratifies patients more likely to respond faster and better to JAK inhibitors vs TH2 biologics. Company expects reimbursement clarity by end of Q3 2026 and potential material revenue contribution in 2027–2028 under traditional reimbursement scenarios.
Improved Profitability Trends and Margins (GAAP Context)
Reported gross margin of 72.8% in Q1 2026 vs 49.2% in Q1 2025 (Q1 2025 included a one‑time accelerated amortization of ~$20.1M). Adjusted EBITDA improved to negative $5.1M from negative $13.0M YoY. Net loss narrowed to $14.5M vs $25.8M YoY; diluted loss per share improved to $0.49 vs $0.90.
Healthy Cash Position and M&A Optionality
As of 03/31/2026, cash, cash equivalents, and marketable securities totaled $261.7M. Management reiterated openness to M&A for strategic fits while not feeling compelled to transact.
CSTL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CSTL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $24.75 | $19.24 | -22.26% |
Feb 26, 2026 | $31.88 | $29.57 | -7.25% |
Nov 03, 2025 | $25.99 | $31.63 | +21.70% |
Aug 04, 2025 | $15.32 | $20.35 | +32.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Castle Biosciences (CSTL) report earnings?
Castle Biosciences (CSTL) is schdueled to report earning on Aug 10, 2026, After Close (Confirmed).
What is Castle Biosciences (CSTL) earnings time?
Castle Biosciences (CSTL) earnings time is at Aug 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CSTL EPS forecast?
CSTL EPS forecast for the fiscal quarter 2026 (Q2) is -0.4.